On Thursday, Shares of General Growth Properties Inc (NYSE:GGP), gained 2.73% to $28.60.
General Growth Properties, declared the return of Adventure to Santa – A DreamWorks DreamPlace: a first-of-its-kind holiday experience that features Shrek, Santa and interactive storytelling with cutting-edge technology. The 2,000-square-foot interactive cottage opens at five GGP locations across the country, adding even more magic and delight to the traditional mall holiday experience.
Reservations can be made online at www.adventuretosanta.com with the purchase of a photo package now through December 24.
Shrek and friends take families on an enchanting journey to the North Pole. Five captivating rooms within the Adventure to Santa experience keep families engaged and entertained, counting a cinematic adventure featuring a wrap-around screen and motion-based effects sure to excite guests of all ages. Once families complete the activities in each room, Adventure to Santa culminates in a special moment where children and their families enjoy a private visit with Santa.
General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls. General Growth Properties, Inc is based in Chicago, Illinois.
Shares of Devon Energy Corp (NYSE:DVN), inclined 1.94% to $44.75, during its last trading session.
Devon Energy Corp., declared plans to issue its third-quarter 2015 earnings news release on Tuesday, Nov. 3, after the close of U.S. financial markets. Please note as soon as practicable after the news release is issued, Devon will post an operations report to its website at www.devonenergy.com.
On Wednesday, Nov. 4, the Company will hold a conference call at 10 a.m. Central Time (11 a.m. Eastern Time), which will comprise primarily of answers to questions from analysts and investors.
Devon Energy Corporation, an independent energy company, primarily engages in the exploration, development, and production of oil, natural gas, and natural gas liquids (NGLs) in the United States and Canada. It holds interests in various properties located in Anadarko Basin, Barnett Shale, Eagle Ford, Mississippian-Woodford Trend, Permian Basin, and Rockies in the United States, in addition to in the Jackfish and Pike heavy oil projects located in Alberta, Canada.
Finally, Shares of Biogen Inc (NASDAQ:BIIB), ended its last trade with 0.18% gain, and closed at $276.83.
Biogen, stated third quarter 2015 results, counting revenues of $2.8 billion, an 11% improvement contrast to the third quarter of 2014. Non-GAAP diluted earnings per share (EPS) for the third quarter of 2015 were $4.48, an improvement of 18% over the third quarter of 2014. Non-GAAP net income attributable to Biogen for the third quarter of 2015 was $1.0 billion, an improvement of 16% over the third quarter of 2014.
On a stated basis, GAAP diluted EPS for the third quarter of 2015 were $4.15, an improvement of 15% over the third quarter of 2014. GAAP net income attributable to Biogen for the third quarter of 2015 was $966 million, an improvement of 13% as compared to the same period in the preceding year.
Biogen also declared a corporate restructuring, which comprises the termination of a number of pipeline programs and an 11% reduction in workforce. These changes are predictable to reduce the current annual run rate of operating expenses by about $250 million. The Company plans to reinvest these savings to support key commercial initiatives, counting raised sales and marketing activities behind TECFIDERA, and the advancement of high potential pipeline candidates in areas such as Alzheimer’s disease, multiple sclerosis, and spinal muscular atrophy.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients.